Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPX887 in Advanced Solid Tumors
NCT06240728Phase 1Recruiting
- Sponsor
- NextPoint Therapeutics
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of npx887 in solid tumor, sponsored by NextPoint Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicity at 21 days, Incidence of Treatment-Emergent Adverse Events at 24 months and 5 more. Started Jan 2024; status: recruiting.
02
Drugs
npx887
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06240728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06240728.